Related Experiment Video
Updated: Dec 13, 2025
Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
Identification of a peptide targeting CD56
Hongxing Huang1, Ying Liu1, Xiaoming Ouyang2
1MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, PR China.
Abstract:
Neural cell adhesion molecule 1 (NCAM1/CD56) is expressed on immune cells, myoblasts, and malignant cells, and there is a growing demand for the genetic detection of CD56 and CD56-targeted therapy. In the present study, we developed a novel peptide ligand (designated Natein) that binds to human CD56 by using T7 phage display technology. Natein recognized the extracellular region of CD56 and could bind to natural killer (NK) cells and CD56-positive (CD56+) cancer cells. CD56+ cells enriched from human peripheral blood mononuclear cells (PBMCs) using biotinylated Natein-conjugated microbeads, similarly to CD56 antibody-isolated cells, demonstrated functional cytotoxicity against K562 cells. In addition, Natein could be used to stain CD56+ lymphoma cells in nasal-type extranodal NK/T-cell lymphoma tissues similarly to a CD56 antibody. These findings suggest that Natein has the potential to be alternative to CD56 antibody that could be used for peptide-based cell isolation and diagnosis.
Insights
Researchers developed Natein, a novel peptide ligand targeting CD56 (NCAM1). This peptide enables effective isolation and diagnosis of CD56-positive cells, including cancer cells and natural killer (NK) cells, offering a potential alternative to CD56 antibodies.
Area of Science:
- Immunology
- Biochemistry
- Molecular Biology
Background:
- Neural cell adhesion molecule 1 (NCAM1/CD56) is a key marker on immune cells, myoblasts, and malignant cells.
- There is a growing need for CD56 detection and targeted therapies.
- Current methods often rely on antibody-based approaches.
Purpose of the Study:
- To develop a novel peptide ligand targeting human CD56.
- To evaluate the potential of this peptide for cell isolation and diagnosis.
Main Methods:
- T7 phage display technology was employed to discover the peptide ligand, named Natein.
- Natein's binding to the extracellular region of CD56 was confirmed.
- Cell isolation and tissue staining assays were performed using Natein.
Main Results:
- Natein successfully binds to natural killer (NK) cells and CD56-positive (CD56+) cancer cells.
- CD56+ cells were effectively enriched from peripheral blood mononuclear cells (PBMCs) using Natein-conjugated microbeads.
- Natein demonstrated comparable performance to CD56 antibodies in staining lymphoma tissues.
Conclusions:
- Natein is a novel peptide ligand that recognizes human CD56.
- Natein shows potential as a peptide-based alternative to CD56 antibodies for cell isolation and diagnosis.
- This peptide offers a promising tool for research and clinical applications involving CD56+ cells.
More Related Videos
08:27Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021